<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308113">
  <stage>Registered</stage>
  <submitdate>7/07/2009</submitdate>
  <approvaldate>22/07/2009</approvaldate>
  <actrnumber>ACTRN12609000609257</actrnumber>
  <trial_identification>
    <studytitle>Study of possible effects of the association of Ginkgo biloba, omega-3 and physical exercise in memory and executive functions of older people with Parkinson's disease.</studytitle>
    <scientifictitle>A randomised controlled trial evaluating the effects of the association of Ginkgo biloba, omega-3 and physical exercise in memory and executive functions of older people with Parkinson's disease.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Parkinson's disease</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Studies of normal psychology, cognitive function and behaviour</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Extract of Ginkgo biloba, omega-3, physical exercise.
All these interventions will be combined together for the treatment group.
The amount of Gingko biloba and omega-3 to be used, respectively, 80mg and 1g per day in capsules, during six months. 
The exercise will envolve coordination, balance, flexibility, strength and aerobic endurance, one hour for sessions, three times a week, during six months.</interventions>
    <comparator>placebo, treatment
Placebo for Ginkgo biloba and omega-3, respectively, talc and liquid paraffin in capsules, taken once a day, during six months.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Executive function with Wisconsin Card Sorting Test (WCST)</outcome>
      <timepoint>Measured at baseline and then reapplied after six months to pre-test, to avoid learning effects.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Cognitive performance.
This outcome will be assessed by questionnaires and tests by the trained professional, pre- and post-intervention with an interval of six months.</outcome>
      <timepoint>Six months from baseline.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Age 60 or older; present clinical diagnosis of Parkinson's disease in the stages from 1 (mild) to 3 (moderate) assessed by the Hoehn and Yahr Scale;not present indication of dementia by results of the Mini-Mental State ExaminationMMSE;not be attending any physical exercise program.</inclusivecriteria>
    <inclusiveminage>60</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Those who not meet the criteria for inclusion; show allergic reaction to substances and not reach 70% of attendance in training.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The procedure for enrolling will do at Brazil Parkinson Association in Sao Paulo. The 80 participants should be diagnosed with Parkinson's disease. Participants will be encoded and after will be realized the randomization.
Participants do not know which groups will be distributed from the beginning of the evaluations. The testing criteria for inclusion are those that determine which participants will be part of the study.
Allocation was concealed if it was done by numbered containers</concealment>
    <sequence>Simple Randomization</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/06/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Universidade Federal de Sao Paulo</primarysponsorname>
    <primarysponsoraddress>Rua Botucatu, 740 
Vila Clementino
Sao Paulo - SP
CEP 04023-900</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Universidade Federal de Sao Paulo</fundingname>
      <fundingaddress>Rua Botucatu, 740 
Vila Clementino
Sao Paulo - SP
CEP 04023-900</fundingaddress>
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)</fundingname>
      <fundingaddress>Caixa Postal: 250
Second floor
Ministerio da Educacao
Brasilia - DF
CEP: 70359-970</fundingaddress>
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Associacao Fundo de Incentivo a Psicofarmacologia (AFIP)</sponsorname>
      <sponsoraddress>Rua Napoleao de Barros, 925
Vila Clementino
Sao Paulo - SP
CEP: 04024-002</sponsoraddress>
      <sponsorcountry>Brazil</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Associacao Brasil Parkinson</othercollaboratorname>
      <othercollaboratoraddress>Avenida Bosque da Saude, 1155
Sao Paulo - SP
CEP: 04142-080
Brazil</othercollaboratoraddress>
      <othercollaboratorcountry>Brazil</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Parkinson's disease can cause cognitive decline. Although the exact cause of neuronal loss in Parkinson's disease remains unknown, current evidence points to the presence of ongoing oxidative stress. The physical exercise can benefit the cognitive function in older people with Parkinson's disease. Ginkgo biloba and omega-3 has been reported to be an antioxidative agent and neuroprotective. We suspect that the combination of the three may potentiate the effect.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comite de Etica em Pesquisa da Universidade Federal de Sao Paulo / Hospital Sao Paulo</ethicname>
      <ethicaddress>Rua Botucatu, 572 - first floor conj 14
Vila Clementino
Sao Paulo - SP
CEP:04023-061</ethicaddress>
      <ethicapprovaldate>23/01/2009</ethicapprovaldate>
      <hrec>1/09/0028</hrec>
      <ethicsubmitdate />
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Katia Tanaka</name>
      <address>Rua Amadeu Luiz Conte, 102
Bosque de Versalles
Araras - SP
CEP: 13609-379</address>
      <phone>+55 19 3542 3054 or +55 19 8175 0542</phone>
      <fax />
      <email>katia@psicobio.epm.br</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Katia Tanaka</name>
      <address>Rua Amadeu Luiz Conte, 102
Bosque de Versalles
Araras - SP
CEP: 13609-379</address>
      <phone>+55 19 3542 3054 or +55 19 8175 0542</phone>
      <fax />
      <email>katia@psicobio.epm.br</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Katia Tanaka</name>
      <address>Rua Amadeu Luiz Conte, 102
Bosque de Versalles
Araras - SP
CEP: 13609-379</address>
      <phone>+55 19 3542 3054 or +55 19 8175 0542</phone>
      <fax />
      <email>katia@psicobio.epm.br</email>
      <country>Brazil</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>